What Is PT-141?

First, PT-141, also known as bremelanotide, is a synthetic cyclic peptide that activates melanocortin receptors. It was developed from the melanocortin research program that produced Melanotan II, but its clinical development shifted away from tanning and toward central nervous-system pathways involved in sexual desire and arousal.

By contrast, phosphodiesterase type 5 inhibitors such as sildenafil or tadalafil, bremelanotide does not primarily act by increasing genital blood flow through nitric-oxide signaling. Its therapeutic action is believed to arise mainly from melanocortin receptor signaling in the brain, including pathways involving the hypothalamus, medial preoptic area, limbic system, and dopamine-associated sexual-motivation networks.

Importantly, the FDA-approved product VYLEESI® treats for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance.

🧬 Molecular Structure

First, bremelanotide is a cyclic heptapeptide analog derived from Melanotan II. It contains a lactam ring formed between the side chains of aspartic acid and lysine. This ring constrains the peptide into a receptor-active shape and improves resistance to enzymatic degradation compared with a flexible linear peptide.

Next, PT-141 differs from Melanotan II primarily at the C-terminus. Bremelanotide contains a free carboxylic acid rather than the C-terminal amide found in Melanotan II. This structural change reduces emphasis on pigmentation while preserving central melanocortin activity relevant to sexual behavior.

🧪 Amino-Acid Sequence

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH

⚛️ Molecular Weight and 🧫 Formula

Therefore, a COA must state whether it reports the free base, acetate salt, hydrate, or another material form. Formula and molecular-weight values differ among these forms.

📅 Discovery Timeline

1980s–early 1990s: Melanocortin analog development

First, researchers developed increasingly potent and stable α-MSH analogs to study pigmentation and melanocortin receptor biology. Melanotan II emerged as a cyclic analog with broad receptor activity.

1990s: Unexpected sexual effects observed

Next, human studies of Melanotan II reported spontaneous erections and changes in sexual desire. These observations suggested that melanocortin signaling could influence central sexual-arousal pathways independently of conventional vascular mechanisms.

Late 1990s–early 2000s: PT-141 created

Then, researchers developed bremelanotide as a metabolite-inspired derivative of Melanotan II. The C-terminal modification reduced its melanotropic emphasis while retaining central prosexual activity.

2000s: Male erectile-response and female-arousal studies

Afterward, early clinical trials evaluated intranasal PT-141 in healthy men, men with erectile dysfunction, and women with sexual-arousal concerns. The program demonstrated biological activity but also identified cardiovascular effects that influenced development strategy.

2010s: Subcutaneous formulation and HSDD development

Meanwhile, clinical development moved to a subcutaneous formulation and focused on acquired, generalized HSDD in premenopausal women.

2019: FDA approval

Finally, on June 21, 2019, the FDA approved VYLEESI for the treatment of premenopausal women with acquired, generalized HSDD under the limitations described in the prescribing information.

Present research

In addition, bremelanotide remains a research tool for studying melanocortin-dependent desire, motivation, dopamine release, sexual behavior, erectile physiology, and central autonomic signaling. Broader applications remain investigational unless separately approved.

📖 Research History

Importantly, the development of bremelanotide is unusual because it began with pigmentation research and evolved into a centrally acting sexual-medicine program. Investigators studying Melanotan II repeatedly observed erectile responses that could not be explained solely by peripheral vasodilation. This redirected attention toward melanocortin receptors in brain regions that organize sexual motivation and behavior.

Next, early human studies showed dose-related erectile responses in men, including some participants with erectile dysfunction. Research then expanded into female sexual-arousal and desire disorders. The most important later evidence came from the two Phase 3 RECONNECT trials, which assessed as-needed subcutaneous bremelanotide in premenopausal women with HSDD.

Moreover, those trials found statistically significant improvements in sexual-desire scores and reductions in distress related to low desire. The average clinical benefit was modest and responses varied. Long-term extension data did not identify new major safety signals, but nausea and transient blood-pressure effects remained important limitations.

🧠 Mechanism of Action

For example, Researchers have not fully established the exact mechanism by which bremelanotide improves HSDD. It is a nonselective melanocortin receptor agonist, and its therapeutic effects are believed to arise mainly through central MC4R-mediated signaling, with possible contributions from MC3R and other melanocortin receptors.

1. Central melanocortin receptor activation

First, bremelanotide reaches functionally relevant central pathways and activates melanocortin receptors in brain regions involved in motivation, reward, autonomic activity, and sexual behavior.

2. Medial preoptic area and hypothalamus

Next, animal and translational studies indicate that MC4R activation in the medial preoptic area of the hypothalamus may increase dopamine release. Dopamine is an excitatory neurotransmitter involved in wanting, anticipation, motivation, and sexual behavior.

3. Limbic and reward networks

Moreover, melanocortin signaling interacts with neural circuits that evaluate salience and reward. Bremelanotide is therefore better described as a modulator of sexual-interest and arousal signaling than as a direct mechanical trigger.

4. Autonomic pathways

In addition, central melanocortin activation can influence sympathetic and parasympathetic output. These autonomic effects may contribute to genital responses but also explain transient increases in blood pressure and reductions in heart rate.

5. Erectile physiology

For example, experimental bremelanotide produced erectile responses through central neural pathways. This differs from sildenafil and tadalafil, which inhibit PDE5 and enhance nitric-oxide-mediated smooth-muscle relaxation in penile tissue.

6. Pigmentation signaling

Finally, bremelanotide can activate MC1R and may cause focal or generalized hyperpigmentation, especially with repeated exposure. Pigmentation is not the therapeutic target of VYLEESI but remains a class-related effect.

🎯 Receptor Profile

Clinical Evidence and Potential Research Areas

Approved use in acquired, generalized HSDD

Importantly, the FDA indication covers premenopausal women whose previously normal desire becomes low across situations and partners, causes marked distress or interpersonal difficulty, and does not result from another condition, relationship issue, or drug effect.

Phase 3 RECONNECT trials

For example, two randomized, placebo-controlled Phase 3 trials evaluated as-needed bremelanotide in premenopausal women with HSDD. Bremelanotide produced statistically significant improvements in validated sexual-desire measures and reductions in distress related to low desire. The trials did not establish a large or uniform response in all participants, and the magnitude of average improvement was modest.

Female sexual arousal research

Moreover, earlier studies evaluated subjective arousal, genital response, sexual satisfaction, and distress. Current interpretation emphasizes desire and distress because those outcomes underpin the approved indication.

Male erectile-dysfunction research

By contrast, intranasal bremelanotide produced erectile responses in early studies of healthy men and men with erectile dysfunction. Research also examined combination use with PDE5 inhibitors. These findings did not result in FDA approval for men or erectile dysfunction.

Dopamine and reward-pathway research

In addition, researchers use bremelanotide to study how melanocortin receptors interact with dopamine, GABA, oxytocin, and hypothalamic circuits involved in sexual motivation.

Appetite and autonomic research

Finally, because MC4R also regulates appetite and cardiovascular autonomic function, researchers continue examining the extent to which therapeutic and adverse effects share overlapping receptor pathways.

Safety, Adverse Effects, and Regulatory Status

Common adverse reactions

First, the approved label identifies nausea as the most common adverse reaction. Other reported effects include:

• First, Flushing
• Next, Headache
• Also, Vomiting
• Moreover, Injection-site reactions
• In addition, Fatigue
• Likewise, Dizziness
• For example, Cough or nasal symptoms in some trial participants

Blood-pressure and heart-rate effects

Importantly, bremelanotide can transiently increase blood pressure and reduce heart rate after administration. VYLEESI is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Cardiovascular risk should be assessed before prescribed use.

Hyperpigmentation

Moreover, focal hyperpigmentation involving the face, gingiva, or breasts has been reported. It may be more likely with repeated exposure and may not fully resolve in every patient.

Renal and hepatic considerations

In addition, severe renal or hepatic impairment may increase drug exposure in severe renal impairment or hepatic impairment. The current prescribing information should be consulted for complete precautions and clinical recommendations.

Limitations of approved use

For example, VYLEESI is not indicated for:

• First, Postmenopausal women
• Next, Men
• Also, Enhancement of sexual performance
• Moreover, Treatment of erectile dysfunction
• In addition, Low desire caused by another medical or psychiatric condition
• Likewise, Low desire caused by relationship problems or medication effects

Unregulated product concerns

However, products sold as “PT-141” outside regulated pharmaceutical channels may differ in peptide identity, salt form, concentration, sterility, endotoxin burden, residual solvents, degradation products, and dose uniformity. A high-purity chromatogram alone does not establish equivalence to VYLEESI.

🧪 Laboratory Testing Methods

First, a scientifically credible analytical program should confirm identity, purity, quantity, chemical form, and relevant contamination risks. Therefore, no single test provides all of this information.

📄 How to Interpret a PT-141 COA

1. Match the exact batch

First, the batch number on the report must match the tested material. A COA from a different lot cannot establish the quality of the current sample.

2. Identify the chemical form

Next, the report should state whether the material is bremelanotide free base, acetate salt, acetate hydrate, or another form. This affects expected mass, assay calculations, and label interpretation.

3. Separate identity, purity, and quantity

• Identity First, asks whether the compound is bremelanotide.
• Purity Next, estimates the proportion of detected material represented by the target peak.
• Assay or net peptide content Also, measures how much target peptide is present.

4. Interpret mass-spectrometry charge states

Moreover, peptides frequently appear as multiply protonated ions. The raw m/z peak may therefore be much lower than the neutral molecular weight. A useful report identifies charge states or provides a deconvoluted mass.

5. Verify cyclization and stereochemistry

However, basic HPLC and intact-mass testing may not fully prove correct lactam-ring formation or D-Phe stereochemistry. Peptide mapping, chiral methods, or other orthogonal analyses can strengthen confirmation.

6. Do not treat “99% purity” as a complete safety result

Likewise, a 99% HPLC result does not establish correct fill amount, sterility, endotoxin level, residual-solvent compliance, elemental purity, or equivalence to an approved injectable product.

7. Review the laboratory and method details

Finally, a useful COA should identify the laboratory, sample identifier, received and test dates, test methods, acceptance criteria, numerical results, reviewer, and report authorization.

📊 PT-141 vs Sildenafil vs Kisspeptin vs Oxytocin

PT-141 vs Melanotan II

🔗 Related Peptides and Compounds

• Melanotan II: First, The cyclic melanocortin analog from which bremelanotide development emerged.
• Afamelanotide: Next, A linear α-MSH analog approved for erythropoietic protoporphyria.
• α-MSH: Also, The endogenous melanocortin peptide that inspired both pigmentation and sexual-function analogs.
• Setmelanotide: Moreover, An MC4R agonist approved for selected rare genetic obesity disorders.
• Kisspeptin: In addition, this reproductive neuropeptide regulates GnRH and has appeared in sexual-emotion research.
• Oxytocin: Likewise, A neuropeptide involved in social behavior, reproduction, lactation, and uterine contraction.

🖼️ Original Diagram Specifications

Diagram 1: PT-141 cyclic structure map

Meanwhile, Create a labeled peptide-ring diagram showing Ac-Nle, the Asp-Lys lactam bridge, His, D-Phe, Arg, Trp, Lys, and the free C-terminal carboxyl group. Include a side-by-side callout showing the C-terminal difference from Melanotan II.

Diagram 2: Central sexual-desire pathway

Likewise, Illustrate bremelanotide entering central signaling pathways, activating MC4R-associated neurons in the medial preoptic area and hypothalamus, increasing dopamine-associated motivation signaling, and influencing desire and arousal. Label the pathway as proposed rather than fully established.

Diagram 3: PT-141 vs PDE5 inhibitor mechanism

In addition, Use a split graphic. The PT-141 side should show brain, hypothalamus, motivation, and autonomic signaling. The sildenafil side should show nitric oxide, cGMP, smooth-muscle relaxation, and penile blood flow.

Diagram 4: Benefit-risk pathway

Moreover, Show therapeutic central melanocortin activation leading toward desire and reduced distress, while parallel autonomic and peripheral receptor activation leads toward nausea, blood-pressure elevation, heart-rate reduction, flushing, and pigmentation.

❓ Frequently Asked Questions

Is PT-141 a peptide?

By contrast, Yes. PT-141 is a synthetic cyclic melanocortin peptide. Its pharmaceutical name is bremelanotide.

Is PT-141 FDA approved?

Also, Yes, but only as the prescription product VYLEESI for premenopausal women with acquired, generalized HSDD meeting the conditions stated in the prescribing information.

Does PT-141 work like Viagra?

Consequently, No. Sildenafil primarily enhances nitric-oxide-dependent blood flow. Bremelanotide acts centrally through melanocortin pathways involved in desire and arousal.

Does PT-141 directly force sexual arousal?

However, No. It modulates central signaling associated with sexual desire and arousal. Individual response depends on biological, psychological, relational, and situational factors.

Can men use PT-141?

Therefore, Men have participated in clinical research involving erectile responses, but VYLEESI is not FDA approved for men or for erectile dysfunction.

Is it approved for postmenopausal women?

For example, No. The current VYLEESI indication is limited to premenopausal women with acquired, generalized HSDD.

What is the most common side effect?

Meanwhile, Nausea is the most common adverse reaction reported with the approved product.

Why can PT-141 affect blood pressure?

Likewise, Central melanocortin receptors participate in autonomic cardiovascular regulation. Activation can temporarily increase blood pressure and reduce heart rate.

Can PT-141 cause skin darkening?

In addition, Yes. Because bremelanotide can activate melanocortin receptors involved in pigmentation, focal or generalized hyperpigmentation can occur.

Does a peptide COA prove that a product is equivalent to VYLEESI?

No. A COA may provide information about a tested sample, but equivalence to an approved drug also depends on formulation, concentration, excipients, device performance, sterility assurance, manufacturing controls, stability, pharmacokinetics, and regulatory review.

Is HPLC purity the same as dose accuracy?

Moreover, No. HPLC purity estimates the composition of detected chromatographic material. Dose accuracy requires a separate quantitative assay or net peptide content measurement.

Is PT-141 a hormone?

By contrast, No. It is a synthetic peptide agonist of melanocortin receptors. It does not replace testosterone, estrogen, or another endogenous sex hormone.

PT-141 Scientific Overview: Final Thoughts

In conclusion, PT-141, or bremelanotide, is a cyclic melanocortin peptide that acts through central neural pathways involved in sexual desire, motivation, arousal, and autonomic function. Its mechanism is fundamentally different from blood-flow medications such as sildenafil and tadalafil.

Importantly, the approved formulation, VYLEESI, has a narrow and clearly defined indication: acquired, generalized HSDD in premenopausal women when low desire causes marked distress and is not explained by another condition, relationship issue, or medication. Research in men, erectile dysfunction, broader libido enhancement, and other populations remains investigational.

Therefore, bremelanotide also demonstrates why receptor pharmacology must be considered as a complete benefit-risk system. The same melanocortin network associated with sexual desire can also influence nausea, pigmentation, blood pressure, heart rate, appetite, and autonomic signaling.

📚 References

Regulatory, Clinical, and Analytical Sources

1. For instance, DailyMed. VYLEESI (bremelanotide injection), current prescribing information.
2. Also, U.S. Food and Drug Administration. VYLEESI prescribing information. 2019.
3. As a result, U.S. Food and Drug Administration. VYLEESI approval package. June 21, 2019.
4. Nevertheless, U.S. Food and Drug Administration. Multidiscipline review for NDA 210557. 2019.
5. Instead, National Center for Biotechnology Information. PubChem Compound Summary: Bremelanotide.
6. Then, National Center for Biotechnology Information. PubChem Compound Summary: Bremelanotide acetate.
7. Meanwhile, Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstetrics & Gynecology. 2019.
8. Likewise, Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics & Gynecology. 2019.
9. For instance, Clayton AH, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. 2019.
10. Also, Cipriani S, et al. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opinion on Pharmacotherapy. 2023.
11. As a result, Althof SE, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. Journal of Sexual Medicine. 2021.
12. Nevertheless, Simon JA, et al. Prespecified and integrated subgroup analyses from the RECONNECT trials. 2022.
13. Instead, Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003.
14. Then, Diamond LE, et al. Double-blind, placebo-controlled evaluation of PT-141 in men. International Journal of Impotence Research. 2004.
15. Meanwhile, Shadiack AM, et al. Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007.
16. Likewise, Ericson MD, et al. Bench-top to clinical therapies: a review of melanocortin ligands from 1954 to 2016. Biochimica et Biophysica Acta. 2017.

Mechanistic and Quality-Control References

17. For instance, Kim S, et al. Novel emerging therapies for erectile dysfunction. World Journal of Men's Health. 2021.
18. Also, Mayer D, Lynch SE. New drug approved for treating hypoactive sexual desire disorder in premenopausal women. Annals of Pharmacotherapy. 2020.
19. As a result, NCBI Bookshelf. Bremelanotide — LiverTox.
20. Nevertheless, ClinicalTrials.gov. Phase 3 study of bremelanotide in premenopausal women with HSDD.
21. Instead, Cone RD, editor. The Melanocortin Receptors. Humana Press.
22. Then, Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992.
23. Meanwhile, Gantz I, Fong TM. The melanocortin system. American Journal of Physiology-Endocrinology and Metabolism. 2003.
24. Likewise, Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocrine Reviews.
25. For instance, International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
26. Also, United States Pharmacopeia. General Chapter <621>, Chromatography.
27. As a result, United States Pharmacopeia. General Chapter <71>, Sterility Tests.
28. Nevertheless, United States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test.
29. Instead, United States Pharmacopeia. General Chapters <232> and <233>, Elemental Impurities.
30. Then, International Council for Harmonisation. ICH Q3C: Impurities—Guideline for Residual Solvents.
31. Meanwhile, International Council for Harmonisation. ICH Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.

Also, Regulatory status, molecular properties, and current labeling were reviewed for this article in July 2026. Always consult the latest official prescribing information for time-sensitive medical and regulatory details.